Tumor eradicated by combination of imiquimod and OX40 agonist for in situ vaccination

Various cancer vaccines have been developed to generate and amplify antigen‐specific T cell responses against malignancy. Among them, in situ vaccination is one of the most practical types as it can trigger immune responses without previous antigen identification. Here we reported a novel in situ va...

Descripción completa

Detalles Bibliográficos
Autores principales: Chu, Yanhong, Li, Rutian, Qian, Lingyu, Liu, Fangcen, Xu, Ruihan, Meng, Fanyan, Ke, Yaohua, Shao, Jie, Yu, Lixia, Liu, Qin, Liu, Baorui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586665/
https://www.ncbi.nlm.nih.gov/pubmed/34537997
http://dx.doi.org/10.1111/cas.15145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586665/
https://www.ncbi.nlm.nih.gov/pubmed/34537997
http://dx.doi.org/10.1111/cas.15145

Ejemplares similares